Objective:To compare the serum levels of transforming growth factor-β1 (TGF-β1),interleukin-17 (IL-17),inter-leukin-23 (IL-23)in patients with bronchial asthma at different degrees of airway obstruction after standardized treatment,in order to explore the significance of TGF-β1,IL-17,IL-23 in airway remodeling in patients with asthma.Methods:Ninety-one asthma patients,who underwent standardized treatment for at least three months,were recruited by applying control study.By using FEV1%pred as grouping criterion,the 91 patients with asthma were divided into the mild asthma group (FEV1%pred≥80%),the moderate asthma group (60 %< FEV1 %< 80%)and the severe asthma group (FEV1 %≤60%).In addition, 27 healthy people were selected as control group.The serum levels of TGF-β1,IL-17,and IL-23 in each group were monitored and compared with each other.Results:1.Compared with that in the control group,the serum levels of TGF-β1 in asthma group were higher,while the levels of IL-17 were lower.There was no significant difference in serum IL-23 level between the two groups.2.Comparison were done among the asthma groups.There were significant differences in serum levels of TGF-β1 and IL-17 between mild asthma group and moderate-to-severe asthma group (P < 0.05 ),while there were no significant differences between moderate group and severe group.3.Serum IL-17 level was correlated negatively with TGF-β1 level. FEV1%pred was correlated negatively with serum TGF-β1 level and positively with serum IL-17 level,while it had no correla-tion with serum IL-23 level.Conclusions:In patients with asthma,the serum TGF-β1 level is negatively correlated with FEV1%pred,which indicates that TGF-β1 is an important index for airway remodeling.The serum levels of IL-17 in patients with asthma is lower than those in healthy people.Furthermore,the decrease of serum IL-17 level is more significant while the obstruction is worse.The probable answer is that persistent airway inflammation inhibits secretion and expression of IL-17,so that the expression of IL-17 declines in phase with severe impairment of pulmonary function and severe airway remodeling.

To evaluate the efficacy of physical therapy (PT) to alleviate symptomatic thoracic radiculopathy (TR) without the use of invasive procedures. Database search was conducted by an experienced medical librarian from inception until January 27, 2023, in EBSCO CINAHL with Full Text, Ovid Cochrane Central Register of Controlled Trials, Ovid Embase, Ovid MEDLINE, Scopus, and Web of Science Core Collection. Inclusion criteria included studies that involved adult patients (age≥18) who had a magnetic resonance imaging-confirmed TR and underwent a structured, supervised PT program of any length. All types of studies were included. Study quality and risk of bias were assessed using the National Heart, Lung, and Blood Institute (NHLBI) Study Quality of Assessment Tool. Certainty in evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. A meta-analysis was not performed. A total of 1,491 studies were screened and 7 studies met inclusion criteria, 5 case studies and 2 cohort studies. All studies showed improvement or resolution of the TR with PT. Quantitative improvements were not noted in most studies and PT regimens were sparsely described. Overall quality assessment demonstrated 3 studies had “good,” 1 “fair,” and 3 “poor” quality evidence. Certainty of evidence was “low” due to risk of bias. A dedicated PT program may help to alleviate symptomatic TR; however due to limited evidence, risk of bias, and low certainty in evidence, the data is too weak to support a definite conclusion.